Sana Biotechnology, Inc. has priced its underwritten public offering of 20,895,522 shares of common stock at $3.35 each, alongside pre-funded warrants for 1,492,537 shares at $3.3499 per warrant, according to the company.
The company said that underwriters have a 30-day option to purchase up to an additional 3,358,208 shares, potentially increasing total offerings. Gross proceeds from the offering are expected to total approximately $75 million before expenses and exclusive of any additional shares underwriters may acquire.
The closing of the offering is anticipated on or about August 8, 2025, subject to customary closing conditions. Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen are serving as joint book-running managers.
This fundraising is intended to strengthen Sana’s balance sheet and support development across its engineered cell therapy programs.
